Arbutus Biopharma Newsroom

Arbutus to Present Imdusiran Data at EASL Congress 2024

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to

GlobeNewswireMay 22 01:00

Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty Vaccine Does Not Infringe Arbutus Patents

Genevant Sciences And Arbutus Biopharma Win Dismissal Of An Action By Acuitas Therapeutics (Partnered With Pfizer On Vaccine Delivery Systems) Seeking A Declaratory Judgement That The Pfizer Comirnaty

BenzingaMay 20 11:52

Sector Update: Health Care Stocks Softer Friday Afternoon

Health care stocks eased Friday afternoon with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) marginally higher. The iShares Biotechnology ETF (IBB) fell 0.3%.

MT NewswiresMay 17 12:53

Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program

Arbutus Biopharma (ABUS) shareholder Whitefort Capital Management issued an open letter to shareholders Friday urging the company to stop further share issuances and explore strategic alternatives for

MT NewswiresMay 17 09:40

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Asserts Arbutus' Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further

BusinesswireMay 17 08:00

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)

TipRanksMay 7 23:41

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu

Arbutus BiopharmaMay 6 23:00

The Arbutus Biopharma Corporation (NASDAQ:ABUS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Last week saw the newest quarterly earnings release from Arbutus Biopharma Corporation (NASDAQ:ABUS), an important milestone in the company's journey to build a stronger business. Revenues fell

Simply Wall StMay 5 07:37

Global RNAi Therapeutics Market Insights & Forecasts With Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been add

BusinesswireMay 3 08:35

Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target

Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma with a Buy and maintains $4 price target.

Analyst UpgradesMay 3 08:21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)

TipRanksMay 3 06:11

Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)

TipRanksMay 2 23:30

Earnings Call Summary | Arbutus Biopharma(ABUS.US) Q1 2024 Earnings Conference

The following is a summary of the Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript:Financial Performance:Arbutus ended Q1 2024 with cash, cash equivalents, and investments of arou

Futu NewsMay 2 17:21 · Conference Call

Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review

Yahoo FinanceMay 2 07:58

Arbutus Biopharma Announces Chief Scientific Officer's Retirement

TipRanksMay 2 06:42

Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, Vs. Street Est of $3.7M

07:34 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (ABUS) ARBUTUS BIOPHARMA CORPORATION Posts Q1 Revenue $1.5M, vs. Street Est of $3.7M

MT NewswiresMay 2 06:34

Arbutus Biopharma 1Q Loss $17.9M >ABUS

Arbutus Biopharma 1Q Loss $17.9M >ABUS

Dow JonesMay 2 06:30

Press Release: Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: A

Dow JonesMay 2 06:25

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virol

Arbutus BiopharmaMay 1 23:00

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a

Arbutus BiopharmaApr 17 23:00